Amylyx Pharmaceuticals announced an infusion of $135 million in Series C funds to support the late-stage development of the Boston-based company’s lead candidate, AMX0035, for amyotrophic lateral sclerosis (ALS). 

Biogen Inc. on July 8 said the U.S. Food and Drug Administration narrowed use of the company’s Alzheimer’s drug after the regulatory agency drew sharp criticism for its broad approval of the drug in June 2021 without proof of clear benefit against the disease.

GlaxoSmithKline Plc and U.S. firm Alector Inc. will together develop antibody-based treatments for Parkinson’s, Alzheimer’s and other similar diseases in a deal worth up to $2.2 billion, the drugmakers said on July 2.

Four biotech companies announced Series A rounds: Vita Therapeutics, NuvoAir, Enveda Biosciences, and ImmuneID.

Preliminary data from Annovis Bio’s Phase II study of ANVS401 shows significant cognitive improvements in Alzheimer’s patients after only one month of treatment.

Placebo response is one of the most significant challenges faced by drug developers who are investigating new pain medications. According to a review of published chronic neuropathic pain trials, placebo responses have increased in magnitude over time, making it even more difficult to definitively demonstrate treatment advantage. Research has also shown that up to 60 percent of study participants may experience placebo-related analgesic responses and that these responses may be persistent.

Researchers from Albert Einstein’s College of Medicine are excited with the recently published findings of an experimental drug that reversed key symptoms of Alzheimer’s disease in mice. 

BrainStorm Cell Therapeutics, one of the leading developers of adult stem cell therapies that mainly focuses on adult neurodegenerative diseases, reported that the company’s 28-week-long Phase II clinical trial for progressive multiple sclerosis (MS) came to a close.

Amathus Therapeutics, a biopharmaceutical company working on small molecule modulators across diverse genetically defined diseases, entered into a strategic collaboration with Merck to develop novel small molecule treatment candidates for neurodegenerative diseases.

Prescription drug watchdog GoodRx compiled a list of the 10 most expensive drugs on the market.